Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Zura Bio Ltd Director's Dealing 2021

Jul 26, 2021

33996_dirs_2021-07-26_f083c668-8433-4916-a299-d23219d099d3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: JATT Acquisition Corp (JATT)
CIK: 0001855644
Period of Report: 2021-07-16

Reporting Person: Athanor Capital, LP (10% Owner)

Holdings (Non-Derivative)

Security Shares Ownership
Class A Ordinary Shares 2388000 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Warrants to Purchase Class A Ordinary Shares $11.50 Class A Ordinary Shares (1194000) Indirect

Footnotes

F1: Athanor Master Fund, LP (the "Master Fund") and Athanor International Master Fund, LP (the "International Master Fund", and together with the Master Fund, the "Funds") are the direct holders of the securities reported herein. Athanor Capital Partners, LP ("Master GP") is the general partner of the Master Fund. Athanor Capital Partners GP, LLC is the general partner of Master GP. Athanor International Fund GP, LP ("International Master GP") is the general partner of the International Master Fund. Athanor International Fund Ultimate GP, LLC is the general partner of International Master GP. Athanor Capital, LP ("Athanor Capital") is the investment adviser to the Funds. Athanor Capital GP, LLC is the general partner of Athanor Capital. Parvinder Thiara is the managing member of Athanor Capital Partners GP, LLC, Athanor International Fund Ultimate GP, LLC and Athanor Capital GP, LLC.

F2: (Continued from footnote 1) By virtue of the foregoing relationships, Mr. Thiara and each of the entities named in this footnote may be deemed to beneficially own the securities held by the Funds, however each of them disclaims beneficial ownership of such securities, except to the extent of his or its pecuniary interest therein.

F3: The Warrants become exercisable on the later of 30 days after the completion of the Issuer's initial business combination or 12 months from the closing of the Issuer's initial public offering on July 16, 2021.

F4: The Warrants expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or the Issuer's liquidation.